Literature DB >> 30125730

Flurbiprofen derivatives as novel α-amylase inhibitors: Biology-oriented drug synthesis (BIODS), in vitro, and in silico evaluation.

Momin Khan1, Aftab Alam2, Khalid Mohammed Khan3, Uzma Salar4, Sridevi Chigurupati5, Abdul Wadood6, Farman Ali4, Jahidul Islam Mohammad7, Muhammad Riaz6, Shahnaz Perveen8.   

Abstract

Novel derivatives of flurbiprofen 1-18 including flurbiprofen hydrazide 1, substituted aroyl hydrazides 2-9, 2-mercapto oxadiazole derivative 10, phenacyl substituted 2-mercapto oxadiazole derivatives 11-15, and benzyl substituted 2-mercapto oxadiazole derivatives 16-18 were synthesized and characterized by EI-MS, 1H and 13C NMR spectroscopic techniques. All derivatives 1-18 were screened for α-amylase inhibitory activity and demonstrated a varying degree of potential ranging from IC50 = 1.04 ± 0.3 to 2.41 ± 0.09 µM as compared to the standard acarbose (IC50 = 0.9 ± 0.04 µM). Out of eighteen compounds, derivatives 2 (IC50 = 1.69 ± 0.1 µM), 3 (IC50 = 1.04 ± 0.3 µM), 9 (IC50 = 1.25 ± 1.05 µM), and 13 (IC50 = 1.6 ± 0.18 µM) found to be excellent inhibitors while rest of the compounds demonstrated comparable inhibition potential. A limited structure-activity relationship (SAR) was established by looking at the varying structural features of the library. In addition to that, in silico study was conducted to understand the binding interactions of the compounds (ligands) with the active site of α-amylase enzyme.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biology-oriented drug synthesis; Flurbiprofen; In silico; In vitro; Novel inhibitors; Structure-activity relationship; α-Amylase

Mesh:

Substances:

Year:  2018        PMID: 30125730     DOI: 10.1016/j.bioorg.2018.07.038

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  6 in total

1.  Biology-oriented drug synthesis (BIODS), in vitro urease inhibitory activity, and in silico studies on ibuprofen derivatives.

Authors:  Faiza Seraj; Khalid Mohammed Khan; Ajmal Khan; Muhammad Ali; Ruqaiya Khalil; Zaheer Ul-Haq; Shehryar Hameed; Muhammad Taha; Uzma Salar; Shahnaz Perveen
Journal:  Mol Divers       Date:  2020-01-21       Impact factor: 2.943

2.  Syntheses, in vitro, and in silico studies of rhodanine-based schiff bases as potential α-amylase inhibitors and radicals (DPPH and ABTS) scavengers.

Authors:  Samuel Attah Egu; Irfan Ali; Khalid Mohammed Khan; Sridevi Chigurupati; Urooj Qureshi; Uzma Salar; Muhammad Taha; Shatha Ghazi Felemban; Vijayan Venugopal; Zaheer Ul-Haq
Journal:  Mol Divers       Date:  2022-05-23       Impact factor: 2.943

3.  Bio-Oriented Synthesis of Novel (S)-Flurbiprofen Clubbed Hydrazone Schiff's Bases for Diabetic Management: In Vitro and In Silico Studies.

Authors:  Aftab Alam; Mumtaz Ali; Najeeb Ur Rehman; Saeed Ullah; Sobia Ahsan Halim; Abdul Latif; Ajmal Khan; Obaid Ullah; Shujaat Ahmad; Ahmed Al-Harrasi; Manzoor Ahmad
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

4.  Identification of potential TNF-α inhibitors: from in silico to in vitro studies.

Authors:  Komal Zia; Sajda Ashraf; Almas Jabeen; Maria Saeed; Mohammad Nur-E-Alam; Sarfaraz Ahmed; Adnan J Al-Rehaily; Zaheer Ul-Haq
Journal:  Sci Rep       Date:  2020-12-01       Impact factor: 4.379

5.  Inhibitory Potential of New Phenolic Hydrazide-Hydrazones with a Decoy Substrate Fragment towards Laccase from a Phytopathogenic Fungus: SAR and Molecular Docking Studies.

Authors:  Halina Maniak; Michał Talma; Mirosław Giurg
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

6.  Synthesis of Novel Benzimidazole-Based Thiazole Derivatives as Multipotent Inhibitors of α-Amylase and α-Glucosidase: In Vitro Evaluation along with Molecular Docking Study.

Authors:  Rafaqat Hussain; Shahid Iqbal; Mazloom Shah; Wajid Rehman; Shoaib Khan; Liaqat Rasheed; Fazal Rahim; Ayed A Dera; Sana Kehili; Eslam B Elkaeed; Nasser S Awwad; Majed A Bajaber; Mohammed Issa Alahmdi; Hamad Alrbyawi; Hashem O Alsaab
Journal:  Molecules       Date:  2022-09-30       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.